These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

158 related articles for article (PubMed ID: 6305175)

  • 1. Dopamine agonists in the treatment of Parkinson's disease.
    Rinne UK
    Adv Neurol; 1983; 37():141-50. PubMed ID: 6305175
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Management of levodopa failures: the use of dopamine agonists.
    Lieberman AN; Gopinathan G; Neophytides A; Goldstein M
    Clin Neuropharmacol; 1986; 9 Suppl 2():S9-21. PubMed ID: 3297319
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Bromocriptine in Parkinson disease.
    Lieberman AN; Goldstein M
    Pharmacol Rev; 1985 Jun; 37(2):217-27. PubMed ID: 3901046
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Treatment of parkinson's disease with bromocriptine.
    Lieberman A; Kupersmith M; Estey E; Goldstein M
    N Engl J Med; 1976 Dec; 295(25):1400-4. PubMed ID: 989885
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Treatment of Parkinson's disease with multiple drugs].
    Kuno S
    Nihon Rinsho; 1997 Jan; 55(1):59-64. PubMed ID: 9014424
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Treatment of Parkinson's disease with the ergoline derivatives CQ 32-084 and CU 32-085.
    Pakkenberg H; Jensen I
    Adv Neurol; 1983; 37():151-7. PubMed ID: 6344587
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Dopamine agonists as primary treatment in Parkinson's disease.
    Rinne UK
    Adv Neurol; 1987; 45():519-23. PubMed ID: 3103394
    [No Abstract]   [Full Text] [Related]  

  • 8. Treatment of Parkinson's disease: levodopa as the first choice.
    Katzenschlager R; Lees AJ
    J Neurol; 2002 Sep; 249 Suppl 2():II19-24. PubMed ID: 12375059
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Treatment of Parkinson's disease with 8-alpha-amino-ergoline, CU 32-085.
    Schneider E; Hubener K; Fischer PA
    Neurology; 1983 Apr; 33(4):468-72. PubMed ID: 6682193
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [A comparative study of the effect of bromocriptine and pergolide on Parkinson disease].
    de Yébenes JG; García-Ruiz PJ; Sánchez-Pernaute R
    Rev Neurol; 1997 Sep; 25(145):1343-5. PubMed ID: 9377286
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Initial treatment of Parkinson's disease].
    Kulisevsky J; López-Villegas D
    Rev Neurol; 1997 Aug; 25 Suppl 2():S163-9. PubMed ID: 9280684
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Adjuvant treatment of Parkinson's disease with dopamine agonists: open trial with bromocriptine and CU 32-085.
    Jellinger K
    J Neurol; 1982; 227(2):75-88. PubMed ID: 6180142
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Dopamine agonists used as monotherapy in de novo PD patients: comparisons with selegiline.
    Lieberman A
    Neurology; 1992 Apr; 42(4 Suppl 4):37-40; discussion 41-8. PubMed ID: 1350073
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Ropinirole as an adjunct to levodopa in the treatment of Parkinson's disease: a 16-week bromocriptine controlled study.
    Im JH; Ha JH; Cho IS; Lee MC
    J Neurol; 2003 Jan; 250(1):90-6. PubMed ID: 12527999
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Initial therapy for Parkinson's disease: levodopa vs. dopamine receptor agonists.
    Kondo T
    J Neurol; 2002 Sep; 249 Suppl 2():II25-9. PubMed ID: 12375060
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Bromocriptine as the 1st treatment of Parkinson's disease. Long term results].
    Rascol A; Montastruc JL; Guiraud-Chaumeil B; Clanet M
    Rev Neurol (Paris); 1982; 138(5):401-8. PubMed ID: 7146724
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparative efficacy of pergolide and bromocriptine in patients with advanced Parkinson's disease.
    Lieberman AN; Neophytides A; Leibowitz M; Gopinathan G; Pact V; Walker R; Goodgold A; Goldstein M
    Adv Neurol; 1983; 37():95-108. PubMed ID: 6858782
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Hypersexuality--a complication of dopaminergic therapy in Parkinson's disease.
    Vogel HP; Schiffter R
    Pharmacopsychiatria; 1983 Jul; 16(4):107-10. PubMed ID: 6685318
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The Parkinson-Control study: a 1-year randomized, double-blind trial comparing piribedil (150 mg/day) with bromocriptine (25 mg/day) in early combination with levodopa in Parkinson's disease.
    Castro-Caldas A; Delwaide P; Jost W; Merello M; Williams A; Lamberti P; Aguilar M; Del Signore S; Cesaro P;
    Mov Disord; 2006 Apr; 21(4):500-9. PubMed ID: 16267842
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Relating mode of action to clinical practice: dopaminergic agents in Parkinson's disease.
    Riederer P; Gerlach M; Müller T; Reichmann H
    Parkinsonism Relat Disord; 2007 Dec; 13(8):466-79. PubMed ID: 17919963
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.